Log In

Forgot Password?
Create New Account

Loading... please wait

2022 Annual Meeting | C158 - Frontotemporal Dementia

Thursday 04/07/22
01:00 PM - 03:00 PM PDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Bradley F. Boeve, MD, FAAN
Aging, Dementia, and Behavioral Neurology
Participants should become familiar with the key clinical, neuropsychological, and neuroimaging aspects of frontotemporal dementia, as well as the current and future management/treatment considerations for those with frontotemporal dementia.
2.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student
Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:30 PM PDT Speaker Clinical and Neuropsychological Aspects of FTD
Bradley F. Boeve, MD, FAAN
01:00 PM - 01:00 PM PDT Speaker Walk-in Slides
Bradley F. Boeve, MD, FAAN
01:30 PM - 02:00 PM PDT Speaker Neuroimaging Aspects of FTD
Howard J. Rosen, MD
02:00 PM - 02:30 PM PDT Speaker Management/Treatment Aspects of FTD
Peter A. Ljubenkov, MD
02:30 PM - 03:00 PM PDT Discussion Open Discussion
Bradley F. Boeve, MD, FAAN, Howard J. Rosen, MD, Peter A. Ljubenkov, MD
Faculty Disclosures
Bradley F. Boeve, MD, FAAN Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Howard J. Rosen, MD Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Peter A. Ljubenkov, MD Dr. Ljubenkov has nothing to disclose.